In the last trading session, 37.93 million Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares changed hands as the company’s beta touched 0.90. With the company’s per share price at $5.13 changed hands at $0.07 or 1.38% during last session, the market valuation stood at $2.09B. RXRX’s last price was a discount, traded about -140.94% off its 52-week high of $12.36. The share price had its 52-week low at $3.79, which suggests the last value was 26.12% up since then. When we look at Recursion Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 28.59 million shares, with the 3-month average coming to 25.09 million.
Analysts gave the Recursion Pharmaceuticals Inc (RXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.43. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RXRX as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX was in green as seen at the end of in last trading. With action -1.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -32.28%, with the 5-day performance at -1.72% in the red. However, in the 30-day time frame, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 22.73% up. Looking at the short shares, we see there were 120.08 million shares sold at short interest cover period of 4.45 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 14.5% from its current market value. According to analyst projections, RXRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -16.96% plunge from its current level, while the stock would need to soar -16.96% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -35.28%. The 2025 estimates are for Recursion Pharmaceuticals Inc earnings to increase by 15.16%, but the outlook for the next 5-year period is at 25.10% per year.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-05.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.10% of Recursion Pharmaceuticals Inc shares while 74.16% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.15%. There are 74.16% institutions holding the Recursion Pharmaceuticals Inc stock share, with ARK INVESTMENT MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 11.6199% of the shares, roughly 28.14 million RXRX shares worth $211.07 million.
BAILLIE GIFFORD & CO holds the second largest percentage of outstanding shares, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30.
Among Mutual Funds, the top two as of May 31, 2025 were ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . With 18.3 shares estimated at $93.87 million under it, the former controlled 4.58% of total outstanding shares. On the other hand, ARK ETF Trust-ARK Genomic Revolution ETF held about 2.82% of the shares, roughly 11.26 shares worth around $57.77 million.
